Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05515601 · ClinicalTrials.gov registry record · Phase 1
A Bioequivalence Study of Mirikizumab (LY3074828) in Healthy Participants
A Phase 1 study, sponsored by Eli Lilly and Company.
- Completed
- Registry status
- Phase 1
- Development phase
- 396
- Enrollment target
NCT05515601: Completed Phase 1 study, sponsored by Eli Lilly and Company.
NCT05515601 is a Phase 1 study that has completed, run by Eli Lilly and Company. The registered enrollment target is 396 participants, above the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (560% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05515601, a Phase 1 study, has completed, sponsored by Eli Lilly and Company.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 396 participants
- Enrollment target
Study Summary
The main purpose of this study is to evaluate amount of mirikizumab (test) that gets into the blood stream and how long it takes the body to get rid of it, when given via autoinjector compared to mirikizumab (reference) solution given via autoinjector. The information about any adverse effects experienced will be collected and the tolerability of mirikizumab will also be evaluated. Screening is required within 35 days prior to enrolment. For each participant, the total duration of the clinical trial will be about 17 weeks including screening.
Primary Outcome
PK: Cmax of mirikizumab was evaluated.
Interventions
- DRUG Mirikizumab
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 396 participants |
| Start Date | 2022-08-31 |
| Est. Completion | 2023-02-20 |
| Phase | Phase 1 |
What the finished NCT05515601 record still lists
NCT05515601 is an interventional study that assigns participants to a tested intervention. The registered 396 participants enrollment target is mid-sized for trials with a published cap, above the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (560% higher).
The record links to 0 conditions, and to 1 intervention - of which Mirikizumab is the first listed.
NCT05515601 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT05515601 about?
NCT05515601 is a clinical study titled "A Bioequivalence Study of Mirikizumab (LY3074828) in Healthy Participants". The main purpose of this study is to evaluate amount of mirikizumab (test) that gets into the blood stream and how long it takes the body to get rid of it, when given via autoinjector compared to mirikizumab (reference) solution given via autoinjector. The information about any adverse effects exper...
What is the current status of trial NCT05515601?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 396 participants. The study started on 2022-08-31. Estimated completion is 2023-02-20.
What interventions are being tested in trial NCT05515601?
The interventions under investigation include: Mirikizumab (DRUG).
Who is sponsoring clinical trial NCT05515601?
This trial is sponsored by Eli Lilly and Company, which has 1,341 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT05515601's enrollment target sits among peer trials
396 77th of 2000 higher than 1,924 of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT05633615 · 396 participants · Phase 2
Testing Drug Treatments After CAR T-cell Therapy in Patients With Relapsed/Refractory Diffuse Large B-cell Lymphoma
- NCT06227910 · 396 participants · Phase 3
A Study of Vedolizumab With and Without Upadacitinib in Adults With Crohn's Disease
- NCT06545331 · 396 participants · Phase 1
Study of XB010 in Subjects With Solid Tumors
- NCT06666790 · 396 participants · NA
DermaSensor Postmarket Surveillance Study
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI